191 related articles for article (PubMed ID: 31312900)
1. Interferon beta increases NK cell cytotoxicity against tumor cells in patients with nasopharyngeal carcinoma via tumor necrosis factor apoptosis-inducing ligand.
Makowska A; Franzen S; Braunschweig T; Denecke B; Shen L; Baloche V; Busson P; Kontny U
Cancer Immunol Immunother; 2019 Aug; 68(8):1317-1329. PubMed ID: 31312900
[TBL] [Abstract][Full Text] [Related]
2. Interferon β and Anti-PD-1/PD-L1 Checkpoint Blockade Cooperate in NK Cell-Mediated Killing of Nasopharyngeal Carcinoma Cells.
Makowska A; Braunschweig T; Denecke B; Shen L; Baloche V; Busson P; Kontny U
Transl Oncol; 2019 Sep; 12(9):1237-1256. PubMed ID: 31295651
[TBL] [Abstract][Full Text] [Related]
3. Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1.
Makowska A; Meier S; Shen L; Busson P; Baloche V; Kontny U
Cancer Immunol Immunother; 2021 Feb; 70(2):323-336. PubMed ID: 32737537
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy Combined with PD-1 Inhibition Increases NK Cell Cytotoxicity towards Nasopharyngeal Carcinoma Cells.
Makowska A; Lelabi N; Nothbaum C; Shen L; Busson P; Tran TTB; Eble M; Kontny U
Cells; 2021 Sep; 10(9):. PubMed ID: 34572108
[TBL] [Abstract][Full Text] [Related]
5. The Role of NK Cells in EBV Infection and EBV-Associated NPC.
Png YT; Yang AZY; Lee MY; Chua MJM; Lim CM
Viruses; 2021 Feb; 13(2):. PubMed ID: 33671917
[TBL] [Abstract][Full Text] [Related]
6. Interferon beta induces apoptosis in nasopharyngeal carcinoma cells
Makowska A; Wahab L; Braunschweig T; Kapetanakis NI; Vokuhl C; Denecke B; Shen L; Busson P; Kontny U
Oncotarget; 2018 Mar; 9(18):14228-14250. PubMed ID: 29581840
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of the killing mechanism of human natural killer cells against hepatocellular carcinoma cell lines HepG2 and Hep3B.
Kim HR; Park HJ; Park JH; Kim SJ; Kim K; Kim J
Cancer Immunol Immunother; 2004 May; 53(5):461-70. PubMed ID: 14648068
[TBL] [Abstract][Full Text] [Related]
8. Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cells.
Sheard MA; Asgharzadeh S; Liu Y; Lin TY; Wu HW; Ji L; Groshen S; Lee DA; Seeger RC
J Immunother; 2013 Jun; 36(5):319-29. PubMed ID: 23719242
[TBL] [Abstract][Full Text] [Related]
9. EBV-Upregulated B7-H3 Inhibits NK cell-Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression.
Chen H; Duan X; Deng X; Huang Y; Zhou X; Zhang S; Zhang X; Liu P; Yang C; Liu G; Ren Q; Xiong Y; Zhu B; Zhang J; Xiang T
Cancer Immunol Res; 2023 Jun; 11(6):830-846. PubMed ID: 36996321
[TBL] [Abstract][Full Text] [Related]
10. Genetic variants in NKG2D axis and susceptibility to Epstein-Barr virus-induced nasopharyngeal carcinoma.
Viet NH; Trung NQ; Dong LT; Trung LQ; Espinoza JL
J Cancer Res Clin Oncol; 2021 Mar; 147(3):713-723. PubMed ID: 33392659
[TBL] [Abstract][Full Text] [Related]
11. Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma.
Zheng Y; Parsonage G; Zhuang X; Machado LR; James CH; Salman A; Searle PF; Hui EP; Chan AT; Lee SP
Cancer Immunol Res; 2015 Oct; 3(10):1138-47. PubMed ID: 25711537
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive single-cell transcriptomic and proteomic analysis reveals NK cell exhaustion and unique tumor cell evolutionary trajectory in non-keratinizing nasopharyngeal carcinoma.
Chen C; Wang C; Pang R; Liu H; Yin W; Chen J; Tao L
J Transl Med; 2023 Apr; 21(1):278. PubMed ID: 37098551
[TBL] [Abstract][Full Text] [Related]
13. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection.
Stegmann KA; Björkström NK; Veber H; Ciesek S; Riese P; Wiegand J; Hadem J; Suneetha PV; Jaroszewicz J; Wang C; Schlaphoff V; Fytili P; Cornberg M; Manns MP; Geffers R; Pietschmann T; Guzmán CA; Ljunggren HG; Wedemeyer H
Gastroenterology; 2010 May; 138(5):1885-97. PubMed ID: 20334827
[TBL] [Abstract][Full Text] [Related]
14. Activated monocytes augment TRAIL-mediated cytotoxicity by human NK cells through release of IFN-γ.
Sarhan D; D'Arcy P; Wennerberg E; Lidén M; Hu J; Winqvist O; Rolny C; Lundqvist A
Eur J Immunol; 2013 Jan; 43(1):249-57. PubMed ID: 22996291
[TBL] [Abstract][Full Text] [Related]
15. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.
Berg M; Lundqvist A; McCoy P; Samsel L; Fan Y; Tawab A; Childs R
Cytotherapy; 2009; 11(3):341-55. PubMed ID: 19308771
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis.
Smyth MJ; Cretney E; Takeda K; Wiltrout RH; Sedger LM; Kayagaki N; Yagita H; Okumura K
J Exp Med; 2001 Mar; 193(6):661-70. PubMed ID: 11257133
[TBL] [Abstract][Full Text] [Related]
17. Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy.
Hu J; Li Y; Li H; Shi F; Xie L; Zhao L; Tang M; Luo X; Jia W; Fan J; Zhou J; Gao Q; Qiu S; Wu W; Zhang X; Liao W; Bode AM; Cao Y
Theranostics; 2020; 10(26):11921-11937. PubMed ID: 33204320
[TBL] [Abstract][Full Text] [Related]
18. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
19. Cytokines elevated in patients with HBV-related acute-on-chronic liver failure promote NK cell mediated cytotoxicity through TRAIL.
Wan Z; Xie G; Wu Y; Liu F; Xin S; You S; Liu H; Li C; Li D
Dig Liver Dis; 2016 May; 48(5):528-535. PubMed ID: 26860239
[TBL] [Abstract][Full Text] [Related]
20. TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells.
Lelaidier M; Dìaz-Rodriguez Y; Cordeau M; Cordeiro P; Haddad E; Herblot S; Duval M
Oncotarget; 2015 Oct; 6(30):29440-55. PubMed ID: 26320191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
